[
1. Boolell M, Allen MJ, Ballard SA, Gepi-Attee S, Muirhead GJ, Naylor AM, et al. Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction. Int J Impot Res. 1996;8(2):47-52.
]Search in Google Scholar
[
2. Boolell M, Gepi-Attee S, Gingell JC, Allen MJ. Sildenafil, a novel effective oral therapy for male erectile dysfunction. Br J Urol. 1996;78(2):257-61.10.1046/j.1464-410X.1996.10220.x
]Search in Google Scholar
[
3. Goldstein I, Lue TF, Padma-Nathan H, Rosen RC, Steers WD, Wicker PA. Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group. N Engl J Med. 1998; 338(20): 1397-404.10.1056/NEJM199805143382001
]Search in Google Scholar
[
4. FDA approves oral therapy for erectile dysfunction. Am J Health Syst Pharm. 1998;55(10):981-98410.1093/ajhp/55.10.981a
]Search in Google Scholar
[
5. Hellstrom WJ, Gittelman M, Karlin G, Segerson T, Thibonnier M, Taylor T, Padma-Nathan H; Vardenafil Study Group. Sustained efficacy and tolerability of vardenafil, a highly potent selective phosphodiesterase type 5 inhibitor, in men with erectile dysfunction: results of a randomized, double-blind, 26-week placebo-controlled pivotal trial. Urology. 2003;61(4 Suppl 1):8-14.10.1016/S0090-4295(03)00115-8
]Search in Google Scholar
[
6. Govier F, Potempa AJ, Kaufman J, Denne J, Kovalenko P, Ahuja S. A multicenter, randomized, double-blind, crossover study of patient preference for tadalafil 20 mg or sildenafil citrate 50 mg during initiation of treatment for erectile dysfunction. Clin Ther. 2003 Nov;25(11):2709-23.10.1016/S0149-2918(03)80328-4
]Search in Google Scholar
[
7. Limin M, Johnsen N, Hellstrom WJ. Avanafil, a new rapid-onset phosphodiesterase 5 inhibitor for the treatment of erectile dysfunction. Expert Opin Investig Drugs. 2010;19(11):1427-37.10.1517/13543784.2010.51895520939743
]Search in Google Scholar
[
8. Mendes GD, dos Santos Filho HO, dos Santos Pereira A, Mendes FD, Ilha JO, Alkharfy KM, et al. A Phase I clinical trial of lodenafil carbonate, a new phosphodiesterase Type 5 (PDE5) inhibitor, in healthy male volunteers. Int J Clin Pharmacol Ther. 2012;50(12):896-906.10.5414/CP20162423073140
]Search in Google Scholar
[
9. Moon KH, Kim SW, Moon du G, Kim JJ, Park NC, Lee SW, et al. A Phase 3 Study to Evaluate the 1-Year Efficacy and Safety of Udenafil 75 mg Once Daily in Patients With Erectile Dysfunction. J Sex Med. 2016;13(8):1263-9.10.1016/j.jsxm.2016.05.01127319276
]Search in Google Scholar
[
10. Du W, Li J, Fan N, Shang P, Wang Z, Ding H. Efficacy and safety of mirodenafil for patients with erectile dysfunction: a meta-analysis of three multicenter, randomized, double-blind, placebo-controlled clinical trials. Aging Male. 2014;17(2):107-11.10.3109/13685538.2013.85811424219508
]Search in Google Scholar
[
11. Hwang IC, Kim YJ, Park JB, Yoon YE, Lee SP, Kim HK, et al. Pulmonary hemodynamics and effects of phosphodiesterase type 5 inhibition in heart failure: a meta-analysis of randomized trials. BMC Cardiovasc Disord. 2017;17(1):150.10.1186/s12872-017-0576-4546895128606099
]Search in Google Scholar
[
12. Anderson SG, Hutchings DC, Woodward M, Rahimi K, Rutter MK, Kirby M, et al. Phosphodiesterase type-5 inhibitor use in type 2 diabetes is associated with a reduction in all-cause mortality. Heart. 2016;102(21):1750-1756.10.1136/heartjnl-2015-309223
]Search in Google Scholar
[
13. Wang L, Chopp M, Szalad A, Jia L, Lu X, Lu M, et al. Sildenafil ameliorates long term peripheral neuropathy in type II diabetic mice. PLoS One. 2015;10(2):e0118134.10.1371/journal.pone.0118134
]Search in Google Scholar
[
14. Wang L, Chopp M, Szalad A, Liu Z, Bolz M, Alvarez FM, et al. Phosphodiesterase- 5 is a therapeutic target for peripheral neuropathy in diabetic mice. Neuroscience. 2011; 193: 399-410.10.1016/j.neuroscience.2011.07.039
]Search in Google Scholar
[
15. El-Mahdy NA, El-Sayad Mel-S, El-Kadem AH. Combination of telmisartan with sildenafil ameliorate progression of diabetic nephropathy in streptozotocin-induced diabetic model. Biomed Pharmacother. 2016; 81: 136-44.10.1016/j.biopha.2016.04.001
]Search in Google Scholar
[
16. Afsar B, Ortiz A, Covic A, Gaipov A, Esen T, Goldsmith D, et al. Phosphodiesterase type 5 inhibitors and kidney disease. Int Urol Nephrol. 2015; 47(9): 1521-8.10.1007/s11255-015-1071-4
]Search in Google Scholar
[
17. Zhang R, Wang Y, Zhang L, Zhang Z, Tsang W, Lu M, et al. Sildenafil (Viagra) induces neurogenesis and promotes functional recovery after stroke in rats. Stroke. 2002; 33(11): 2675-80.10.1161/01.STR.0000034399.95249.59
]Search in Google Scholar
[
18. Ding G, Jiang Q, Li L, Zhang L, Zhang Z, Lu M, et al. Longitudinal magnetic resonance imaging of sildenafil treatment of embolic stroke in aged rats. Stroke. 2011; 42(12): 3537-41.10.1161/STROKEAHA.111.622092
]Search in Google Scholar
[
19. Zhang L, Zhang Z, Zhang RL, Cui Y, LaPointe MC, Silver B, et al. Tadalafil, a long-acting type 5 phosphodiesterase isoenzyme inhibitor, improves neurological functional recovery in a rat model of embolic stroke. Brain Res. 2006; 1118(1): 192-8.10.1016/j.brainres.2006.08.028
]Search in Google Scholar
[
20. Ölmestig JNE, Marlet IR, Hainsworth AH, Kruuse C. Phosphodiesterase 5 inhibition as a therapeutic target for ischemic stroke: A systematic review of preclinical studies. Cell Signal. 2017;38:39-48.10.1016/j.cellsig.2017.06.015
]Search in Google Scholar
[
21. Ghofrani HA, Wiedemann R, Rose F, Schermuly RT, Olschewski H, Weissmann N, et al. Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial. Lancet. 2002; 360(9337): 895-900.10.1016/S0140-6736(02)11024-5
]Search in Google Scholar
[
22. Kumazoe M, Sugihara K, Tsukamoto S, Huang Y, Tsurudome Y, Suzuki T, et al. 67-kDa laminin receptor increases cGMP to induce cancer-selective apoptosis. J Clin Invest. 2013;123(2):787-99.10.1172/JCI64768356182423348740
]Search in Google Scholar
[
23. Marques JG, Gaspar VM, Markl D, Costa EC, Gallardo E, Correia IJ. Co-delivery of Sildenafil (Viagra(®)) and Crizotinib for synergistic and improved anti-tumoral therapy. Pharm Res. 2014; 31(9): 2516-28.10.1007/s11095-014-1347-x24623484
]Search in Google Scholar
[
24. Bender AT, Beavo JA. Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use. Pharmacol Rev. 2006;58(3):488-520.10.1124/pr.58.3.516968949
]Search in Google Scholar
[
25. Yoo TH, Pedigo CE, Guzman J, Correa-Medina M, Wei C, Villarreal R, et al. Sphingomyelinase-like phosphodiesterase 3b expression levels determine podocyte injury phenotypes in glomerular disease. J Am Soc Nephrol. 2015; 26(1): 133-47.10.1681/ASN.2013111213427973624925721
]Search in Google Scholar
[
26. Amirjanians M, Egemnazarov B, Sydykov A, Kojonazarov B, Brandes R, Luitel H, et al. Chronic intratracheal application of the soluble guanylyl cyclase stimulator BAY 41-8543 ameliorates experimental pulmonary hypertension. Oncotarget. 2017; 8(18): 29613-29624.10.18632/oncotarget.16769544469028410199
]Search in Google Scholar
[
27. Lee DI, Zhu G, Sasaki T, Cho GS, Hamdani N, Holewinski R, et al. Phosphodiesterase 9A controls nitric-oxide-independent cGMP and hypertrophic heart disease. Nature. 2015; 519(7544): 472-6.10.1038/nature14332437660925799991
]Search in Google Scholar
[
28. Matsui H, Sopko NA, Hannan JL, Bivalacqua TJ. Pathophysiology of erectile dysfunction. Curr Drug Targets. 2015; 16(5): 411-9.10.2174/13894501160515050411404125950641
]Search in Google Scholar
[
29. Movsesian MA, Kukreja RC. Phosphodiesterase inhibition in heart failure. Handb Exp Pharmacol. 2011; (204): 237-49.10.1007/978-3-642-17969-3_1021695643
]Search in Google Scholar
[
30. Bender AT, Beavo JA. Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use. Pharmacol Rev. 2006; 58(3): 488-520.10.1124/pr.58.3.5
]Search in Google Scholar
[
31. Beavo JA. Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. Physiol Rev. 1995; 75(4): 725-48.10.1152/physrev.1995.75.4.7257480160
]Search in Google Scholar
[
32. Boswell-Smith V, Spina D, Page CP. Phosphodiesterase inhibitors. Br J Pharmacol. 2006; 147 (Suppl 1): S252-7.10.1038/sj.bjp.0706495
]Search in Google Scholar
[
33. Francis SH, Blount MA, Corbin JD. Mammalian cyclic nucleotide phosphodiesterases: molecular mechanisms and physiological functions. Physiol Rev. 2011; 91(2): 651-90.10.1152/physrev.00030.2010
]Search in Google Scholar
[
34. Ahmad F, Murata T, Shimizu K, Degerman E, Maurice D, Manganiello V. Cyclic nucleotide phosphodiesterases: important signaling modulators and therapeutic targets. Oral Dis. 2015; 21(1): e25-50.10.1111/odi.12275
]Search in Google Scholar
[
35. Coquil JF, Franks DJ, Wells JN, Dupuis M, Hamet P. Characteristics of a new binding protein distinct from the kinase for guanosine 3’:5’-monophosphate in rat platelets. Biochim Biophys Acta. 1980; 631(1): 148-65.10.1016/0304-4165(80)90063-X
]Search in Google Scholar
[
36. Francis SH, Lincoln TM, Corbin JD. Characterization of a novel cGMP binding protein from rat lung. J Biol Chem. 1980; 255(2): 620-6.10.1016/S0021-9258(19)86221-X
]Search in Google Scholar
[
37. Kotera J, Fujishige K, Omori K. Immunohistochemical localization of cGMP-binding cGMP-specific phosphodiesterase (PDE5) in rat tissues. J Histochem Cytochem. 2000; 48(5): 685-93.10.1177/00221554000480051210769052
]Search in Google Scholar
[
38. Shimizu-Albergine M, Rybalkin SD, Rybalkina IG, Feil R, Wolfsgruber W, Hofmann F, et al. Individual cerebellar Purkinje cells express different cGMP phosphodiesterases (PDEs): in vivo phosphorylation of cGMP-specific PDE (PDE5) as an indicator of cGMPdependent protein kinase (PKG) activation. J Neurosci. 2003; 23(16): 6452-9.10.1523/JNEUROSCI.23-16-06452.2003
]Search in Google Scholar
[
39. Akand M, Gencer E, Yaman Ö, Erişgen G, Tekin D, Özdiler E. Effect of sildenafil on platelet function and platelet cGMP of patients with erectile dysfunction. Andrologia. 2015; 47(10): 1098-102.10.1111/and.1238725486996
]Search in Google Scholar
[
40. Sasser JM, Ni XP, Humphreys MH, Baylis C. Increased renal phosphodiesterase-5 activity mediates the blunted natriuretic response to a nitric oxide donor in the pregnant rat. Am J Physiol Renal Physiol. 2010; 299(4): F810-4.10.1152/ajprenal.00117.2010295726120668100
]Search in Google Scholar
[
41. Santos AI, Carreira BP, Nobre RJ, Carvalho CM, Araújo IM. Stimulation of neural stem cell proliferation by inhibition of phosphodiesterase 5. Stem Cells Int. 2014; 2014: 878397.10.1155/2014/878397391448024550991
]Search in Google Scholar
[
42. Peixoto CA, Nunes AK, Garcia-Osta A. Phosphodiesterase-5 Inhibitors: Action on the Signaling Pathways of Neuroinflammation, Neurodegeneration, and Cognition. Mediators Inflamm. 2015; 2015: 940207.10.1155/2015/940207468182526770022
]Search in Google Scholar
[
43. Murthy KS. Activation of phosphodiesterase 5 and inhibition of guanylate cyclase by cGMP-dependent protein kinase in smooth muscle. Biochem J. 2001; 360(Pt 1): 199-208.10.1042/bj3600199
]Search in Google Scholar
[
44. Dhooghe B, Noël S, Bouzin C, Behets-Wydemans G, Leal T. Correction of chloride transport and mislocalization of CFTR protein by vardenafil in the gastrointestinal tract of cystic fibrosis mice. PLoS One. 2013; 8(10): e77314.10.1371/journal.pone.0077314381197724204804
]Search in Google Scholar
[
45. Turko IV, Francis SH, Corbin JD. Studies of the molecular mechanism of discrimination between cGMP and cAMP in the allosteric sites of the cGMP-binding cGMP-specific phosphodiesterase (PDE5). J Biol Chem. 1999; 274(41): 29038-41.10.1074/jbc.274.41.2903810506154
]Search in Google Scholar
[
46. Kotera J, Francis SH, Grimes KA, Rouse A, Blount MA, Corbin JD. Allosteric sites of phosphodiesterase-5 sequester cyclic GMP. Front Biosci. 2004; 9: 378-86.10.2741/123114766375
]Search in Google Scholar
[
47. Corbin JD, Turko IV, Beasley A, Francis SH. Phosphorylation of phosphodiesterase-5 by cyclic nucleotide-dependent protein kinase alters its catalytic and allosteric cGMP-binding activities. Eur J Biochem. 2000; 267(9): 2760-7.10.1046/j.1432-1327.2000.01297.x10785399
]Search in Google Scholar
[
48. Francis SH, Bessay EP, Kotera J, Grimes KA, Liu L, Thompson WJ, et al. Phosphorylation of isolated human phosphodiesterase-5 regulatory domain induces an apparent conformational change and increases cGMP binding affinity. J Biol Chem. 2002; 277(49): 47581-7.10.1074/jbc.M20608820012359732
]Search in Google Scholar
[
49. Al-Shboul O, Mahavadi S, Sriwai W, Grider JR, Murthy KS. Differential expression of multidrug resistance protein 5 and phosphodiesterase 5 and regulation of cGMP levels in phasic and tonic smooth muscle. Am J Physiol Gastrointest Liver Physiol. 2013; 305(4): G314-24.10.1152/ajpgi.00457.2012389121123764893
]Search in Google Scholar
[
50. Castro LR, Schittl J, Fischmeister R. Feedback control through cGMP-dependent protein kinase contributes to differential regulation and compartmentation of cGMP in rat cardiac myocytes. Circ Res. 2010; 107(10): 1232-40.10.1161/CIRCRESAHA.110.22671220847310
]Search in Google Scholar
[
51. Mullershausen F, Lange A, Mergia E, Friebe A, Koesling D. Desensitization of NO/cGMP signaling in smooth muscle: blood vessels versus airways. Mol Pharmacol. 2006; 69(6): 1969-74.10.1124/mol.105.02090916510560
]Search in Google Scholar
[
52. Stegbauer J, Friedrich S, Potthoff SA, Broekmans K, Cortese-Krott MM, Quack I, et al. Phosphodiesterase 5 attenuates the vasodilatory response in renovascular hypertension. PLoS One. 2013; 8(11): e80674.10.1371/journal.pone.0080674382987224260450
]Search in Google Scholar
[
53. Lin CS. Phosphodiesterase type 5 regulation in the penile corpora cavernosa. J Sex Med. 2009; 6 Suppl 3: 203-9.10.1111/j.1743-6109.2008.01179.x19267844
]Search in Google Scholar
[
54. Murthy KS. Contractile agonists attenuate cGMP levels by stimulating phosphorylation of cGMP-specific PDE5; an effect mediated by RhoA/PKC-dependent inhibition of protein phosphatase 1. Br J Pharmacol. 2008; 153(6): 1214-24.10.1038/sj.bjp.0707686227544118204475
]Search in Google Scholar
[
55. Rybalkin SD, Rybalkina IG, Feil R, Hofmann F, Beavo JA. Regulation of cGMP-specific phosphodiesterase (PDE5) phosphorylation in smooth muscle cells. J Biol Chem. 2002; 277(5): 3310-7.10.1074/jbc.M10656220011723116
]Search in Google Scholar
[
56. Frame MJ, Tate R, Adams DR, Morgan KM, Houslay MD, Vandenabeele P, Pyne NJ. Interaction of caspase-3 with the cyclic GMP binding cyclic GMP specific phosphodiesterase (PDE5a1). Eur J Biochem. 2003; 270(5): 962-70.10.1046/j.1432-1033.2003.03464.x12603329
]Search in Google Scholar
[
57. Lin CS. Tissue expression, distribution, and regulation of PDE5. Int J Impot Res. 2004; 16 Suppl 1: S8-S10.10.1038/sj.ijir.390120715224128
]Search in Google Scholar
[
58. Reffelmann T, Kloner RA. Therapeutic potential of phosphodiesterase 5 inhibition for cardiovascular disease. Circulation. 2003; 108(2): 239-44.10.1161/01.CIR.0000081166.87607.E212860892
]Search in Google Scholar
[
59. Sopory S, Kaur T, Visweswariah SS. The cGMP-binding, cGMP-specific phosphodiesterase (PDE5): intestinal cell expression, regulation and role in fluid secretion. Cell Signal. 2004; 16(6): 681-9210.1016/j.cellsig.2003.11.00415093609
]Search in Google Scholar
[
60. Scipioni A, Giorgi M, Nuccetelli V, Stefanini S. Immunohistochemical localisation of PDE5 in rat lung during pre- and postnatal development. J Biomed Biotechnol. 2009; 2009: 932961.10.1155/2009/932961273047219707527
]Search in Google Scholar
[
61. Kedia GT, Ückert S, Oelke M, Sonnenberg JE, Sohn M, Kuczyk MA, Hedlund P. Expression and distribution of phosphodiesterase isoenzymes in the human male urethra. Urology. 2015; 85(4): 964.e1-6.10.1016/j.urology.2014.12.03025704994
]Search in Google Scholar
[
62. Fibbi B, Morelli A, Vignozzi L, Filippi S, Chavalmane A, De Vita G, Marini M, Gacci M, Vannelli GB, Sandner P, Maggi M. Characterization of phosphodiesterase type 5 expression and functional activity in the human male lower urinary tract. J Sex Med. 2010; 7(1 Pt 1): 59-69.10.1111/j.1743-6109.2009.01511.x19796053
]Search in Google Scholar
[
63. Zhu B, Vemavarapu L, Thompson WJ, Strada SJ. Suppression of cyclic GMP-specific phosphodiesterase 5 promotes apoptosis and inhibits growth in HT29 cells. J Cell Biochem. 2005; 94(2): 336-50.10.1002/jcb.2028615526282
]Search in Google Scholar
[
64. Li Q, Shu Y. Pharmacological modulation of cytotoxicity and cellular uptake of anti-cancer drugs by PDE5 inhibitors in lung cancer cells. Pharm Res. 2014; 31(1): 86-96.10.1007/s11095-013-1134-0386461423884568
]Search in Google Scholar
[
65. Catalano S, Campana A, Giordano C, Győrffy B, Tarallo R, Rinaldi A, Bruno G, Ferraro A, Romeo F, Lanzino M, Naro F, Bonofiglio D, Andò S, Barone I. Expression and Function of Phosphodiesterase Type 5 in Human Breast Cancer Cell Lines and Tissues: Implications for Targeted Therapy. Clin Cancer Res. 2016; 22(9): 2271-82.10.1158/1078-0432.CCR-15-190026667489
]Search in Google Scholar
[
66. Hamilton TK, Hu N, Kolomitro K, Bell EN, Maurice DH, Graham CH, Siemens DR. Potential therapeutic applications of phosphodiesterase inhibition in prostate cancer. World J Urol. 2013; 31(2): 325-30.10.1007/s00345-012-0848-722383129
]Search in Google Scholar
[
67. Piazza GA, Thompson WJ, Pamukcu R, Alila HW, Whitehead CM, Liu L, Fetter JR, Gresh WE Jr, Klein-Szanto AJ, Farnell DR, Eto I, Grubbs CJ. Exisulind, a novel proapoptotic drug, inhibits rat urinary bladder tumorigenesis. Cancer Res. 2001; 61(10): 3961-8.
]Search in Google Scholar
[
68. Karami-Tehrani F, Moeinifard M, Aghaei M, Atri M. Evaluation of PDE5 and PDE9 expression in benign and malignant breast tumors. Arch Med Res. 2012; 43(6): 470-5.10.1016/j.arcmed.2012.08.00622960860
]Search in Google Scholar
[
69. Booth L, Roberts JL, Cruickshanks N, Conley A, Durrant DE, Das A, Fisher PB, Kukreja RC, Grant S, Poklepovic A, Dent P. Phosphodiesterase 5 inhibitors enhance chemotherapy killing in gastrointestinal/genitourinary cancer cells. Mol Pharmacol. 2014; 85(3): 408-19.10.1124/mol.113.090043393515524353313
]Search in Google Scholar
[
70. Marino N, Collins JW, Shen C, Caplen NJ, Merchant AS, Gökmen-Polar Y, Goswami CP, Hoshino T, Qian Y, Sledge GW Jr, Steeg PS. Identification and validation of genes with expression patterns inverse to multiple metastasis suppressor genes in breast cancer cell lines. Clin Exp Metastasis. 2014; 31(7): 771-86.10.1007/s10585-014-9667-0494875325086928
]Search in Google Scholar
[
71. Ryu YK, Lee MH, Lee J, Lee JW, Jang SJ, Kang JH, Moon EY. γ-Irradiated cancer cells promote tumor growth by activation of Toll-like receptor 1-mediated inducible nitric oxide synthase in macrophages. J Leukoc Biol. 2015; 97(4): 711-21.10.1189/jlb.3A0114-055R25632046
]Search in Google Scholar
[
72. Li L, Zhu L, Hao B, Gao W, Wang Q, Li K, Wang M, Huang M, Liu Z, Yang Q, Li X, Zhong Z, Huang W, Xiao G, Xu Y, Yao K, Liu Q. iNOS-derived nitric oxide promotes glycolysis by inducing pyruvate kinase M2 nuclear translocation in ovarian cancer. Oncotarget. 2017; 8(20): 33047-33063.10.18632/oncotarget.16523546484928380434
]Search in Google Scholar
[
73. Basudhar D, Somasundaram V, de Oliveira GA, Kesarwala A, Heinecke JL, Cheng RY, Glynn SA, Ambs S, Wink DA, Ridnour LA. Nitric Oxide Synthase-2-Derived Nitric Oxide Drives Multiple Pathways of Breast Cancer Progression. Antioxid Redox Signal. 2017; 26(18): 1044-1058.10.1089/ars.2016.6813548834827464521
]Search in Google Scholar
[
74. Liu Y, Wang Y, Hu Y, Ge S, Li K, Wang S, Li L. The apoptotic inducible effects of salicylic acid on hepatoma cell line: relationship with nitric oxide signaling. J Cell Commun Signal. 2017. doi: 10.1007/s12079-017-0380-z.10.1007/s12079-017-0380-z555939428185215
]Search in Google Scholar
[
75. Günzle J, Osterberg N, Saavedra JE, Weyerbrock A. Nitric oxide released from JS-K induces cell death by mitotic catastrophe as part of necrosis in glioblastoma multiforme. Cell Death Dis. 2016; 7(9): e2349.10.1038/cddis.2016.254505985827584787
]Search in Google Scholar
[
76. Burke AJ, Sullivan FJ, Giles FJ, Glynn SA. The yin and yang of nitric oxide in cancer progression. Carcinogenesis. 2013; 34(3): 503-12.10.1093/carcin/bgt03423354310
]Search in Google Scholar
[
77. Cheng H, Wang L, Mollica M, Re AT, Wu S, Zuo L. Nitric oxide in cancer metastasis. Cancer Lett. 2014; 353(1): 1-7.10.1016/j.canlet.2014.07.014415083725079686
]Search in Google Scholar
[
78. Bian K, Murad F. Nitric oxide (NO)--biogeneration, regulation, and relevance to human diseases. Front Biosci. 2003; 8: d264-78.10.2741/99712456375
]Search in Google Scholar
[
79. Bian K, Ghassemi F, Sotolongo A, Siu A, Shauger L, Kots A, Murad F. NOS-2 signaling and cancer therapy. IUBMB Life. 2012; 64(8): 676-83.10.1002/iub.105722715033
]Search in Google Scholar
[
80. Chang WL, Masih S, Thadi A, Patwa V, Joshi A, Cooper HS, Palejwala VA, Clapper ML, Shailubhai K. Plecanatide-mediated activation of guanylate cyclase-C suppresses inflammation-induced colorectal carcinogenesis in Apc(+/Min-FCCC) mice. World J Gastrointest Pharmacol Ther. 2017;8(1):47-59.10.4292/wjgpt.v8.i1.47529260628217374
]Search in Google Scholar
[
81. Cesarini V, Martini M, Vitiani LR, Gravina GL, Di Agostino S, Graziani G, D’Alessandris QG, Pallini R, Larocca LM, Rossi P, Jannini EA, Dolci S. Type 5 phosphodiesterase regulates glioblastoma multiforme aggressiveness and clinical outcome. Oncotarget. 2017;8(8):13223-13239.10.18632/oncotarget.14656535509128099939
]Search in Google Scholar
[
82. Bian K, Murad F. sGC-cGMP signaling: target for anticancer therapy. Adv Exp Med Biol. 2014;814:5-13.10.1007/978-1-4939-1031-1_225015797
]Search in Google Scholar
[
83. Crocetti E. (2015). Centre for Parliamentary Studies. Retrieved November 15th 2017, from https://ec.europa.eu/jrc/en/publication/epidemiology-prostate-cancer-europe
]Search in Google Scholar
[
84. Hirik E, Bozkurt A, Karabakan M, Onuk Ö, Balcı MB, Aydın M, Çakan M, Nuhoglu B. Results of tadalafil treatment in patients following an open nerve-sparing radical prostatectomy. Arch Ital Urol Androl. 2016; 88(1): 4-6.10.4081/aiua.2016.1.427072168
]Search in Google Scholar
[
85. Liu N, Mei L, Fan X, Tang C, Ji X, Hu X, Shi W, Qian Y, Hussain M, Wu J, Wang C, Lin S, Wu X. Phosphodiesterase 5/protein kinase G signal governs stemness of prostate cancer stem cells through Hippo pathway. Cancer Lett. 2016; 378(1): 38-50.10.1016/j.canlet.2016.05.01027179930
]Search in Google Scholar
[
86. Das A, Durrant D, Mitchell C, Dent P, Batra SK, Kukreja RC. Sildenafil (Viagra) sensitizes prostate cancer cells to doxorubicin-mediated apoptosis through CD95. Oncotarget. 2016; 7(4): 4399-413.10.18632/oncotarget.6749482621426716643
]Search in Google Scholar
[
87. Koka S, Das A, Zhu SG, Durrant D, Xi L, Kukreja RC. Long-acting phosphodiesterase-5 inhibitor tadalafil attenuates doxorubicin-induced cardiomyopathy without interfering with chemotherapeutic effect. J Pharmacol Exp Ther. 2010; 334(3): 1023-30.10.1124/jpet.110.170191293967320543097
]Search in Google Scholar
[
88. Ammirante M, Shalapour S, Kang Y, Jamieson CA, Karin M. Tissue injury and hypoxia promote malignant progression of prostate cancer by inducing CXCL13 expression in tumor myofibroblasts. Proc Natl Acad Sci U S A. 2014; 111(41):14776-81.10.1073/pnas.1416498111420563725267627
]Search in Google Scholar
[
89. Chavez AH, Scott Coffield K, Hasan Rajab M, Jo C. Incidence rate of prostate cancer in men treated for erectile dysfunction with phosphodiesterase type 5 inhibitors: retrospective analysis. Asian J Androl. 2013; 15(2): 246-8.10.1038/aja.2012.162373916223353723
]Search in Google Scholar
[
90. Jamnagerwalla J, Howard LE, Vidal AC, Moreira DM, Castro-Santamaria R, Andriole GL, Freedland SJ. The Association between Phosphodiesterase Type 5 Inhibitors and Prostate Cancer: Results from the REDUCE Study. J Urol. 2016; 196(3): 715-20.10.1016/j.juro.2016.03.172501469527060053
]Search in Google Scholar
[
91. Jo JK, Kim K, Lee SE, Lee JK, Byun SS, Hong SK. Phosphodiesterase Type 5 Inhibitor Use Following Radical Prostatectomy is not Associated with an Increased Risk of Biochemical Recurrence. Ann Surg Oncol. 2016; 23(5): 1760-7.10.1245/s10434-015-5059-126717939
]Search in Google Scholar
[
92. Michl U, Molfenter F, Graefen M, Tennstedt P, Ahyai S, Beyer B, Budäus L, Haese A, Heinzer H, Oh SJ, Salomon G, Schlomm T, Steuber T, Thederan I, Huland H, Tilki D. Use of phosphodiesterase type 5 inhibitors may adversely impact biochemical recurrence after radical prostatectomy. J Urol. 2015; 193(2): 479-83.10.1016/j.juro.2014.08.11125196656
]Search in Google Scholar
[
93. Zhang R, Wang Y, Zhang L, Zhang Z, Tsang W, Lu M, Zhang L, Chopp M. Sildenafil (Viagra) induces neurogenesis and promotes functional recovery after stroke in rats. Stroke. 2002; 33(11): 2675-80.10.1161/01.STR.0000034399.95249.5912411660
]Search in Google Scholar
[
94. Koneru S, Varma Penumathsa S, Thirunavukkarasu M, Vidavalur R, Zhan L, Singal PK, Engelman RM, Das DK, Maulik N. Sildenafil-mediated neovascularization and protection against myocardial ischaemia reperfusion injury in rats: role of VEGF/angiopoietin-1. J Cell Mol Med. 2008; 12(6B): 2651-64.10.1111/j.1582-4934.2008.00319.x382888118373738
]Search in Google Scholar
[
95. Magnon C, Hall SJ, Lin J, Xue X, Gerber L, Freedland SJ, Frenette PS. Autonomic nerve development contributes to prostate cancer progression. Science. 2013; 341(6142): 1236361.10.1126/science.123636123846904
]Search in Google Scholar
[
96. Ronca R, Benkheil M, Mitola S, Struyf S, Liekens S. Tumor angiogenesis revisited: Regulators and clinical implications. Med Res Rev. 2017. doi: 10.1002/med.21452.10.1002/med.2145228643862
]Search in Google Scholar
[
97. El-Naa MM, Othman M, Younes S. Sildenafil potentiates the antitumor activity of cisplatin by induction of apoptosis and inhibition of proliferation and angiogenesis. Drug Des Devel Ther. 2016; 10: 3661-3672.10.2147/DDDT.S107490511787327895461
]Search in Google Scholar
[
98. Bora GS, Gupta VG, Mavuduru RS. Re: Use of Phosphodiesterase Type 5 Inhibitors May Adversely Impact Biochemical Recurrence after Radical Prostatectomy: U. Michl, F. Molfenter, M. Graefen, P. Tennstedt, S. Ahyai, B. Beyer, L. Budäus, A. Haese, H. Heinzer, S. J. Oh, G. Salomon, T. Schlomm, T. Steuber, I. Thederan, H. Huland and D. Tilki J Urol 2015; 193: 479-483. J Urol. 2016; 195(3): 804;10.1016/j.juro.2015.08.10326627733
]Search in Google Scholar
[
99. Gallina A, Bianchi M, Gandaglia G, Cucchiara V, Suardi N, Montorsi F, Briganti A. A Detailed Analysis of the Association Between Postoperative Phosphodiesterase Type 5 Inhibitor Use and the Risk of Biochemical Recurrence After Radical Prostatectomy. Eur Urol. 2015; 68(5): 750-3.10.1016/j.eururo.2015.02.00225700565
]Search in Google Scholar
